Chlamydia trachomatis ga qarshi antitanachalar, IgA
Kod:18002
| Kabi | Chlamydia trachomatis ga qarshi IgA |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Ferment bilan bog'langan immunosorbent analiz (ELISA)
Kutilayotgan natija topshirish vaqti
1–2 kun
Maxsus tayyorlik
- Avoid smoking for at least 30 minutes before the specimen is collected.
Qanday foydalanish
Chlamydia trachomatis ga qarshi antitanachalar, IgA (Anti‑Chlamydia trachomatis IgA) xlamidiy infeksiyaning faolligi va bosqichini baholash hamda antimikrob terapiyani boshlash bo‘yicha qarorlarni qo‘llab‑quvvatlash uchun qo‘llanadi. Ketma‑ket (takroriy) tekshiruvlar antibiotiklarga javobni baholash va davolashni davom ettirish, to‘xtatish yoki o‘zgartirish zarurligini belgilashga yordam beradi. Homiladorlikda, ona jinsiy yo‘llari yallig‘lanishi mavjud bo‘lsa, ushbu test perinatal yuqish ehtimolini baholashga hissa qo‘shishi mumkin. Natijalar klinik ko‘rinish va, mavjud bo‘lsa, nuklein kislotalarni amplifikatsiya qilish testi (NAAT) bilan uyg‘un holda baholanishi lozim.
Cheklovlar
Chlamydia trachomatis majburiy hujayra ichi mikroorganizmi bo‘lib, ikki bosqichli rivojlanish sikliga ega: u hujayra tashqarisidagi elementar tanachalar (antibiotiklarga nisbatan kam sezgir) va hujayra ichidagi retikulyar tanachalar (antibiotiklarga sezgir) o‘rtasida almashinadi. U urogenital yo‘llar, to‘g‘ri ichak, orofarenks va kon’yunktiva shilliq qavat epiteliysini zararlaydi hamda peripartum davrida yuqishi mumkin, bu esa yangi tug‘ilgan chaqaloqlarda kon’yunktivit va pnevmoniyaga olib kelishi mumkin. Gumoral javob IgM, IgA va IgG ni o‘z ichiga oladi; ular infeksiyaning turli fazalari bilan mos keladi. IgA o‘tkir shilliq qavat infeksiyasi yoki reaktivatsiyaning markeridir; u odatda birlamchi infeksiyadan keyin 10–15 kunda paydo bo‘ladi, so‘ng pasayadi, biroq persistiruvchi yoki surunkali infeksiyada yuqori bo‘lib qolishi mumkin. Ayollarda ko‘tariluvchi infeksiya salpingit, tuxum yo‘llarining tutilishi, bepushtlik va ektopik homiladorlikka olib kelishi mumkin; erkaklarda esa uretrit va epididimit odatiy ko‘rinishlardir. Serologik topilmalar klinik baholash va to‘g‘ridan‑to‘g‘ri aniqlash usullari bilan integratsiya qilinishi lozim.
| Referens oraliq | — |
|---|---|
| Ko'rsatmalar | Suspected urogenital chlamydial infection, including cervicitis or urethritis, Infertility workup as part of the diagnostic evaluation, Assessment of neonatal conjunctivitis or pneumonia, Staging of chlamydial infection, Monitoring the response to antibiotic therapy, Genital or urinary tract inflammation during pregnancy |
Natija og'ishlarining mumkin sabablari
Pasaygan daraja
- early infection (<2 weeks from onset)
Namunangiz talablari
| Namunangiz | To'liq qon |
|---|---|
| Container | Lavanda qopqoqli probirka (K3 EDTA) |
| Hajm | 1 mL (min 0.5 mL) |
| Saqlash tayyorlik | Sovutilgan, Muzlatilgan |
References
Black C.M. Current methods of laboratory diagnosis of Chlamydia trachomatis infections // Clin. Microbiol. Rev. – 1997. – № 10. – стр. 160-184.
Black C.M. Serological tests for Chlamydia trachomatis infections (Author’s Reply) // Clin. Microbiol. Rev. – 1998. – № 11. – P. 228-229.
Centers for Disease Control and Prevention. Recommendations for the prevention and management of Chlamydia trachomatis infections // Morbidity and Mortality Weekly Report. – 1993. – № 42. – RR-12. – P. 1–39.
Ishi K., Shimota H., Kawashima T., Kawahata S., Kubota T., Takada M. Significance of determination of the blood antibody level in Chlamydia trachomatis infection of the uterine cervix // Rinsho Byori. – 1991. – № 39. – P. 1215-1219.
Numazaki K. Serological tests for Chlamydia trachomatis infections (Letter to the Editor) // Clin. Microbiol. Rev. – 1998. – № 11. – P. 228.
Takaba H., Nakano Y., Miyake K. Studies on detection of serum IgA and IgG antibodies specific for Chlamydia trachomatis in latent infections in males // Nippon Hinyokika Gakkai Zasshi. – 1991. – № 82. – P. 1084-1090.
Workowski K.A., Lampe M.F., Wong K.G., Watts M.B., Stamm W.E. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection // JAMA. – 1993. – № 270. – P. 2071–2075.